Fig. 43.1 Results of PNF in patients with stage IV of Dupuytren contracture (group 1). (a) Left hand of a 72-year-old patient with Dupuytren contracture before and 21 days after…
Variable FSC (N = 48) CCH (N = 43) Age (mean + SD) 65.9 (9.2) 65.1 (9.7) Sex (male %) 83.3 88.4 Number of affected digits 64 50 Affected digits…
Fig. 22.1 Assessment of flexion deformity for rays and independent joint. α PED of MCP joint, β PED of PIP joint, α + β TPED of ray. TPED the total…
Fig. 3.1 Surgeon’s preferred choice of treatment depending on stage of disease LF is the favorite option, independent of the Tubiana stage. PNF is being chosen mainly in stages I…
Fig. 47.1 (a): Compression splint in 5th ray; (b) traction splint in 5th ray Fig. 47.2 Illustrative case of a satisfying result after 3 months of compression splinting. (a) Pretreatment,…
Fig. 48.1 Anatomic landmarks for CCH injection The site of injection is midway between the tip of the coracoid and the bicipital groove. Next, the safety and efficacy of injectable…
Fig. 7.1 Measurement of total extension deficit. Patients (n = 25) underwent fasciectomy for Dupuytren Disease. Total extension deficit was measured with a goniometer, with deficit from affected digits added…
Fig. 40.1 (a) Retracted skin in Dupuytren Disease, wherein myofibroblasts are aligned and anchored to the epidermis (brown staining, Alfa smooth muscle actin stained); (b) in contrast, the noninvolved skin…
PICOS analysis Definition Participants Dupuytren Disease of the hand Intervention Surgical treatment/percutaneous fasciotomy/collagenase injection for DD Comparisons Not applicable (systematic review) Outcomes Reported range of movement Study design Included: RCTs,…
Fig. 18.1 Mean flexion contractures from baseline to day 31 Fig. 18.2 Range of motion at baseline and day 31 Table 18.1 Most common treatment-related AEs AE, n (%) (n…
